Devicare, member of CataloniaBio, especialized in innovative medical devices for home care of chronic patients under (Remote Patient Monitoring) has closed a seed round of 3 million euros. This funding will be used to consolidate the launch of clinical studies of two of Devicare's main product lines on the Spanish market: (Lit-Control®) for prevention and self-management of recurring urinary diseases and (Tao-Control®) for self-management of patients who take oral anticoagulants.

The company opened the entrance of investment holding company EMESA, and other Family Offices and Corporate partners. “This profile of investors is without a doubt a large strategic contribution ...

CataloniaBio and HealthTech Cluster have agreed to merge into one entity which is going to encompass more than 200 innovative enterprises, hospitals and knowledge institutions of the Catalan health arena. Both entities General Assemblies of Members, held on 22nd February and 4th May respectively, entrusted the start of the merging process to their executive boards. The merging process will finish, once rectified by the two extraordinary assemblies, with the call for elections at the end of 2017.

To coordinate this period of integration, a steering committee with members of both executive boards  has been created, among them, their CEO’s Ignasi ...

Gebro Spain Pharma, member of CataloniaBio, will promote the creation of new start-ups in pain and autoimmune diseases through an immersion program of Richi Social Entrepreneurs in Boston.

The entrepreneurs interested can submit their applications before June 28th 2017. Those who are selected will take part in a three-week experience that takes place in Boston from 30 October to 17 November 2017, in one of the most innovative and international ecosystems. Start-ups will be able to interact with local experts from various areas, and that will allow them to promote their business projects.

The program value is $ 10,000 ...

Specipig has obtained a certificate of compliance with the principles of Good Laboratory Practices (GLP) from the Department of Health (Government of Catalonia) for conducting trials of toxicity, tolerance and biocompatibility in drugs for human use and healthcare devices.

"This recognition of quality is a step forward in the company's internationalisation process. In 2017 we hope to move into markets such as the United Kingdom and Italy" explains Jaume Amat, CEO of Specipig and member of the board of CataloniaBio.

This certification has been awarded as the result of implementing a wider quality assurance system, allowing the company to ...

Anaconda BioMed, focused on the development of next generation neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke (AIS) has appointed Creganna Medical to develop, test and manufacture its ANCD Brain device. Creganna Medical works for the development of minimally invasive devices and now is enrolled in colaboration with Anaconda BioMed in the final stages of development of the neurovascular device for the company's forthcoming clinical trial to obtain CE approval.

"This is another important step for Anaconda Biomed to secure our path to commercialize our 3rd generation thrombectomy device," said the CEO of Anaconda BioMed, Dr. Ofir Arad ...

Eignapharma, member of CataloniaBio based in TecnoCampus Mataró (Barcelona), is going to offer its counsulting services at the portuguese market. Eignapharma was founded in 2010 and gives suppport to biopharmaceutical companies to start and increase the value of their strategic operations in the areas of regulatory and medical affairs, business development and market access. 

The company is intended to expand its geographical presence to more countries, considering that's an important step forward within its plan of growth. In addition to Portugal, they currently they also have an office in India.

We recommend you to see this CataloniaBio's videointerview of ...

The biopharmaceutical company Oryzon Genomics, member of CataloniaBio, has received an injection of capital of 18.2 million euros from a group of international investors, mostly from the US. The capital increase will be mainly used to finance its research and development of clinical  pipeline candidates. As Oryzon's CEO Carlos Buesa explains: "The positive evolution of our clinical trials and this additional funding strengthens the company to further advance the achievement of significant milestones in the development of our drugs”.

With this capital increase the laboratory also wants to join international institutional investors, specialized in the pharmaceutical industry, as a ...

Vytrus Biotech, a company specialising in plant stem cells and a member of CataloniaBio, has won the international Beauty Industry Awards, with the product Capilia Longa PPF, which reduces hair loss and boosts hair density. The Beauty Industry Awards, organised by CosmeticsDesign, recognise the most significant innovations in the field of cosmetics. This time, 250 products from around the world were submitted to the awards and the judges put special emphasis on the functionality, competitive advantages, ease of formulation, cost-effectiveness and environmental attributes of the product.

This is the first international award a Vytrus Biotech ingredient has won. The company ...

Reig Jofre has inaugurated a new analytical laboratory for development and quality control with the latest technology designed to incorporate rapid microbiology techniques with wich to shorten response time, increase efficiency and reduce costs.

Thanks to this investment, the company will undertake larger scale biotech projects and address the major entry challenges of demanding markets as Japan, Korea, Brazil or USA. The new facilities, located in Sant Joan Despí (Barcelona), has a surface of 1,200 square meters, has meant an investment of 4 million and have 110 workers from the 330 that work in the same place.

This week ...

www.bioingenium.net is the new website Bioingenium has just launched to boost its international presence as a protein-expression specialist. The new site clearly and attractively explains about Bioingenium, the services and products it offers and how it can help pharmaceutical, biotechnology and cosmetic companies to expand and develop bioprocesses to manufacture therapeutic proteins and vaccines for human and animal health. The company currently has laboratories equipped with three platforms: bacterial expression, mammalian expression i yeast expression.

On the new site, Bioingenium explains the values of the company and its team, which focus mainly on communication, quality and customer-orientated service ...

The start-up Made of Genes, linked to ESADE Business School and associated with CataloniaBio, has been the first company in Spain selected, from more than 1000 worldwide, to join the 2nd edition of the Dubai Future Accelerators program, an initiative of the Dubai Future Foundation. For Oscar Flores, CEO of Made of Genes, "this is an important recognition and convert Middle East in a crucial region for the internationalization of the company".

The Dubai Future Accelerators program partners with ground-breaking companies from around the world and gives them the opportunity to find and test new solutions to real-life challenges using ...

Bionure exceeded the one million euros initially expected in its crowdfunding campaign and plans to allocate these resources to the development of BN201, an innovative drug against multiple sclerosis that has the potential to stop the advance of the disease (El Periódico). Multiple sclerosis, which is currently incurable, affects 2.5 million people worldwide, 600,000 in Europe and 47,000 in Spain.

Bionure has granted Spiral Therapeutics a license to develop BN201 and BN119 (for the treatment of the inner ear disorders). Spiral Therapeutics, founded by Hugo Peris in San Francisco (Silicon Valley), will soon start a feasibility assessment ...

Capital Cell, a crowdfunding platform that finances new companies in the life sciences field, has received authorisation from the Financial Conduct Authority and €580,000 from seven British investors to launch the operation in London next 26 April (La Vanguardia). The company has signed a collaboration agreement with Angels in MedCity, a specialised network of 3,500 private investors from London, Oxford and Cambridge that is considered one of the biggest in Europe, and will soon present its first six investment projects in London.

Photo: Daniel Oliver, CEO of Capital Cell. 

A disruptive device surgery for herniated discs, developed under the AR-TEX European project led by the company Neos Surgery, associated with CataloniaBio, has won the category Innovators of tomorrow in the Eureka Innovation awards. The aim now is to launch the new restful invertebral ring device which acts as a buffer between the affected area and nearby nerves. This creates a barrier strong enough to prevent re-herniation.

Every year more than one million patients in Europe undergo surgery to repair herniated discs in the lower lumbar. It is a painful process, expensive and sometimes risky (10% of patients require a ...

In 2017, CataloniaBio is launching a new activity: the CataloniaBio Council. This is geared exclusively towards the CEOs, founding partners and board of directors at member companies. Its goal is twofold: to create a tight-knit group of executives that represent the present and future of the sector and to give them the chance to network and share in the knowledge of top-notch guest speakers.

The first event, held on 23 March at the Barcelona Science Park (PCB), was attended by fifteeen executives of CataloniaBio. TiGenix CEO Eduardo Bravo was present to explain the milestones his company has achieved since it ...

Minoryx Therapeutics announces that it has successfully completed its phase 1 trial with MIN-102. MIN-102 targets X-linked adrenoleukodystrophy (X-ALD), a rare and chronically debilitating life threatening neurodegenerative disease. There are two main clinical phenotypes of X-ALD: adrenomyeloneuropathy (AMN), characterized by progressive motor dysfunction, and inflammatory cerebral ALD (cALD), characterized by severe neuroinflammation leading to early death. There are currently no pharmacological treatments for X-ALD. MIN-102 is the only product in development for potential use across all the main phenotypes.

The phase 1 trial was a combined single- and multiple-ascending dose study with the aim of assessing pharmacokinetics, safety and tolerability ...

La biotecnològica ZeClinics, associada a CataloniaBio, ha tancat un acord comercial amb l'empresa danesa Cobo Scientific per poder oferir els seus serveis al nord d'Europa. Gràcies a aquesta aliança ZeClinics podrà entrar als mercats danès, suec, noruec, finlandès i polonès.

Cobo Scientific es va fundar el gener del 2017 però el seu equip compta amb una experiència de més de 20 anys treballant com a soci comercial d'algunes de les empreses europees més destacades en l'àmbit de la recerca biomèdica i de descobriment de fàrmacs. La seu de l'empresa danesa es troba a Copenhaguen, en un dels clúsers europeus més ...

Photo Gallery

Two companies have received the CataloniaBio 2017 BioSuccess Award in recognition of the milestones they have reached over the past year in the health and life sciences area in Catalonia: Mosaic Biomedicals, a spin-off of the Vall d'Hebron Institute of Oncology (VHIO) and the Vall d'Hebron Research Institute (VHIR) founded by Dr Joan Seoane, Dr Judit Anido and Dr Josep Baselga, and STAT-Diagnostica, created by engineers Jordi Carrera and Rafel Bru.

The awards ceremony took place on the 15th of March as part of the 3rd CataloniaBio Gala Dinner, held at the Maritime Museum of Barcelona ...

Pharmaceutical company Reig Jofre, a CataloniaBio member, is awaiting approval from international healthcare authorities for 100 new drug listings the company is developing over the coming three years. This news was announced by Reig Jofre CEO Ignasi Biosca in Madrid, in his presentation of the company’s results.

Photo: Ignasi Biosca, Reig Jofre CEO and president of CataloniaBio © Ara.cat

Personal genomics start-up Made of Genes, a member of CataloniaBio, and academic group SOLTI have joined forces to “create a high-potential research tool to help address scientific/clinical concerns and expand our knowledge of biology and treating breast cancer,” explained Dr Aleix Prat, coordinator of the Solti Scientific Committee.

You can extend this information to the website Made of Genes.

Photo: Dr. Oscar Flores, CEO Made of Genes. © CataloniaBio